Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsASX:IDX 69 Days Sales Outstanding is 13.22 as of Jun. 2026, which is 3% below its 10-year median of 13.57. GuruFocus rates ASX:IDX with a GF Score™ of 69/100 and a GF Value™ of A$2.64 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 98.01% on this metric.
The historical rank and industry rank for Integral Diagnostics's Days Sales Outstanding or its related term are showing as below:
ASX:IDX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.24 Med: 13.57 Max: 18.32
Current: 13.53
During the past 13 years, Integral Diagnostics's highest Days Sales Outstanding was 18.32. The lowest was 10.24. And the median was 13.57.
ASX:IDX's Days Sales Outstanding is ranked better than 98.01% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs ASX:IDX: 13.53
Integral Diagnostics's Days Sales Outstanding
declined
from Jun. 2025 (14.90) to Jun. 2026 (13.22).
Integral Diagnostics (ASX:IDX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Integral Diagnostics Days Sales Outstanding Related Terms
Integral Diagnostics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Days Sales Outstanding falls into.
Integral Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a Days Sales Outstanding of 13.22 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Integral Diagnostics and its competitors. This is near median its historical median of 13.57. Over the past decade, Integral Diagnostics' Days Sales Outstanding has ranged from 10.24 to 18.32. According to the industry distribution chart, Integral Diagnostics ranks #4 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 2%.
Is Integral Diagnostics' Days Sales Outstanding too high?
Integral Diagnostics' current Days Sales Outstanding of 13.22 is near median its 10-year median of 13.57. Over the past 10 years, this metric has ranged from a low of 10.24 to a high of 18.32. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Integral Diagnostics' value of 13.22 is 80.4% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #4 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #4 out of 201 companies for Days Sales Outstanding. This places Integral Diagnostics in the top 2% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.59. Integral Diagnostics' value of 13.22 is 80.4% below this benchmark. Historically, Integral Diagnostics' own Days Sales Outstanding has ranged from 10.24 to 18.32 over the past decade. While the company's 10-year median is 13.57 vs. the industry median of 67.59, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Days Sales Outstanding of 13.22 is 80.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Days Sales Outstanding is 13.22, which is near median its own 10-year median of 13.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.64, compared to a current price of A$2.28 — trading 13.6% below its estimated fair value. The current Days Sales Outstanding is 13.22, which is near median its 10-year median of 13.57 and 80.4% below the Medical Diagnostics & Research industry median of 67.59. Integral Diagnostics' overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Days Sales Outstanding is 13.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.28 is trading 13.6% below its estimated GF Value™ of A$2.64.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Days Sales Outstanding: 13.22 (near median its 10-year median of 13.57)
GF Value™: A$2.64 vs. price of A$2.28 (13.6% below fair value)
Industry Position: 80.4% below the Medical Diagnostics & Research median (#4 of 201)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
69GF Score
Get the complete analysis for ASX:IDX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
